Search

News Inhibitor of Activated Factor XII Garadacimab in Prophylaxis of HAE Attacks

Hereditary angioedema (HAE) is an autosomal dominant inherited disease characterized by a deficiency of C1 inhibitor. This condition leads to excessive production of bradykinin, which is responsible for the development of soft tissue edema. Garadacimab represents a human antibody, the first of its class, aimed at inhibiting activated factor XII, a key initiator of bradykinin formation. The phase II study presented below, whose results were recently published, evaluated the efficacy and safety of this innovative HAE therapy.

Source: Hereditary Angioedema 14. 11. 2022

News Cenobamate in the Therapy of Pharmacoresistant Epilepsy in a Warfarinized Patient –⁠ A Case Study

A case study from Czech practice presents a patient with pharmacoresistant epilepsy and concurrent warfarin medication for heart valve replacement, where the INR value remained within the cardiologist’s recommended range without further adjustments to anticoagulant therapy during combined antiepileptic therapy with cenobamate (CNB) under the recommended dose titration.

Source: Epilepsy 13. 9. 2023

News Treatment of a patient with colorectal cancer after kidney transplantation –⁠ case report

Patients after organ transplantation currently live to an older age thanks to advances in surgery and pharmacotherapy. However, the longer a person takes immunosuppressants, the more they are at risk of developing malignant disease. The case report of Hungarian doctors from the university hospital in Pécs illustrates what the treatment of metastatic colorectal cancer (mCRC) after kidney transplantation can look like.

Source: Colorectal Cancer 20. 5. 2022

News Composition of the Intestinal Microbiota of Patients with IBS May Predetermine the Success of a Diet with Low Fermentable Carbohydrates

Some patients with irritable bowel syndrome may benefit from a diet low in fermentable carbohydrates, but the mechanism of this intervention is not yet satisfactorily explained. A study published in Gut focused on the relationship between the composition of the intestinal microbiota and clinical response to dietary intervention.

Source: Irritable Bowel Syndrome 23. 7. 2022

News Cardiovascular Risks in Schizophrenics: What Are They Related To and How To Eliminate Them?

Schizophrenia affects about 1% of the population. This disease is associated, among other things, with increased cardiovascular (CV) morbidity and mortality. What is the cause and what to focus on in primary prevention?

Source: Modern Treatment of Schizophrenia 24. 6. 2021

Články časopisu Hormonal contraception and risk of venous thromboembolism

Author of the article: O. Ludka, J. Špinar, V. Musil, Z. Pozdíšek Source: Vnitřní lékařství | 5/2010 15. 5. 2010

News Balance and Rehabilitation –⁠ Firm on the Ground Even with Multiple Sclerosis

A large portion of patients with multiple sclerosis (MS) suffer from balance disorders. What are the options for non-pharmacological therapy for these issues according to the latest studies?

Source: Multiple Sclerosis 1. 11. 2023

News INFOGRAPHIC: Which treatment to choose in the 1st line for a patient with type 2 diabetes?

Diabetes mellitus is a complex chronic disease that requires continuous treatment and a strategy to reduce associated risks beyond mere glycemic control. Comorbidities and the risk of complications are key elements in deciding the choice of therapy for type 2 diabetics. This fact is also considered by the American Diabetes Association (ADA) in its annually published standards of care for patients with diabetes, which brought several changes in 2022.

Source: Diabetes 24. 2. 2023

News When to Switch to Second-Line Treatment for Primary Biliary Cholangitis?

In patients with primary biliary cholangitis (PBC), the response to ursodeoxycholic acid (UDCA) treatment is an important prognostic indicator. To identify patients with an insufficient response to this modality who require second-line therapy, the best practice is to assess the biochemical response to UDCA after 12 months of treatment. A validated and easy-to-use tool is the determination of serum alkaline phosphatase (ALP) activity and serum total bilirubin concentration. Although treatment response to UDCA is commonly checked after 12 months, a 6-month check has the same discriminatory value.

Source: Primary Biliary Cholangitis 10. 12. 2020

News Is the efficacy of bisoprolol in secondary prevention of acute myocardial infarction in patients after percutaneous coronary intervention comparable to carvedilol?

Beta-blockers (BB) are recommended for all patients after percutaneous coronary intervention (PCI) as part of secondary prevention of acute myocardial infarction (AMI). The study presented below compared the efficacy of carvedilol –⁠ a vasodilating beta-blocker, whose benefit in this indication was confirmed by a randomized clinical trial –⁠ with the effect of bisoprolol.

Source: Cardiovascular Continuum 26. 1. 2021

News Cardiovascular Safety of Tofacitinib in Real-World Clinical Practice –⁠ Results of the STAR-RA Study

Recent results from the ORAL Surveillance clinical trial have raised concerns about the cardiovascular adverse effects of tofacitinib in patients with rheumatoid arthritis. A comprehensive analysis of real-world clinical practice data, involving nearly 13,000 patients, focused on the cardiovascular safety of tofacitinib for this indication.

Source: Arthritis 29. 5. 2022

News The Benefit of Dabigatran Over Warfarin Is Greater in Patients with Atrial Fibrillation and Diabetes Than in Nondiabetics

As early as 2015, an analysis of the results of the RE-LY study in patients with atrial fibrillation showed that the reduction in absolute risk of embolic events with dabigatran compared to warfarin is greater in patients with diabetes than in those without diabetes.

Source: Anticoagulant Treatment 24. 4. 2020

News Safety and efficacy of dabigatran and other NOACs compared with warfarin in patients with atrial fibrillation –⁠ results of a large long-term prospective study

Anticoagulant therapy is key in the prevention of strokes in patients with atrial fibrillation. Until the introduction of new oral anticoagulants (NOACs), warfarin was the first-choice drug for these patients, but unlike NOACs, it requires careful dose titration and effect monitoring. The safety and benefits of using various anticoagulants were examined in the study below.

Source: Anticoagulant Treatment 25. 5. 2020

News Patient with generalized malignant melanoma treated with nivolumab in the first line

A 75-year-old patient was referred for examination at the dermato-oncology clinic of the Dermatology Clinic of VFN in September 2016. He was being treated for ICHS and had undergone prostate surgery for hyperplasia in 2013.

Source: Case Studies from Immunooncology 10. 9. 2020

News Comparison of the Effectiveness of Different Types of Toothbrushes in Orthodontic Patients

The aim of the study cited below was to evaluate the efficiency of a manual orthodontic brush, an electric toothbrush with an oscillating head, and a sonic toothbrush in controlling plaque, gingivitis, and interproximal bleeding in patients undergoing orthodontic treatment with fixed appliances and to compare their relative effectiveness.

Source: Dental Care 10. 5. 2023